Laboratory and clinical clues, including markedly elevated testosterone with suppressed LH/FSH, dyslipidemia, hypertension, and liver enzyme elevations, may indicate suspected AAS-related endocrine and metabolic disturbances but require confirmation with repeat testing after discontinuation. This evidence concerns the gene BRD2 and hypertensive disorder.